D	~	Т
1	U	1

٠

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ :		(11) International Publication Number:	WO 90/11296	
C07K 7/10, 7/34, 7/40 A61K 37/02, 37/24	A1	(43) International Publication Date:	4 October 1990 (04.10.90)	
(21) International Application Number: PCT/US	589/01	21 Published With international search report	rt.	
(22) International Filing Date: 20 March 1989	(20.03.)	9)		
(71) Applicant: THE GENERAL HOSPITAL CO TION [US/US]; Fruit Street, Boston, MA 921	ORPOR 14 (US	A -		
(72) Inventor: HABENER, Joel, F. ; 217 Plymouth Ro ton Highlands, MA 02161 (US).	oad, Ne	v-		
(74) Agents: FOX, Samuel, L. et al.; Saidman, Sterne, Goldstein, 1225 Connecticut Avenue, N.W., Washington, DC 20036 (US).	Kessler Suite 3	& 0,		
 (81) Designated States: AT (European patent), BE (patent), CH (European patent), DE (European FR (European patent), GB (European patent), pean patent), JP, LU (European patent), NL (patent), SE (European patent). 	Europe n pater IT (Eu Europe	n),)- n		
(54) Title: INSULINOTROPIC HORMONE				
(57) Abstract				
Derivatives of glucagon-like peptide I (GLP-1) have been found to have insulinotropic activity. The invention pertains to such derivatives, and to the use of such derivatives as a potential therapy for <i>Diabetes Mellitus</i> .				
·				
			1	
	_	······································		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

- AT Austria
- AU BB Australia
- Barbados
- BE Belgium
- BF Burkina Fasso
- BG Bulgaria BJ Benin
- BR Brazil

Canada

- CA CF Central African Republic
- CG Congo
- СН Switzerland

R

DOCKE

Δ

Δ

СМ Cameroon

М

- Germany, Federal Republic of DE DK Denmark
- KP Democratic People's Republic of Korea Republic of Korea KR Liechtenstein u LK Sri Lanka

Spain

Finland

France

Gabon

Italy

Japan

Hungary

United Kingdom

ES

FI

FR

GA

GB

HU

Π

JP

w Luxembourg MC Monaco

- Madagascar MG
- ML Mali Mauritania MR
- MW Malawi
- NL Netherlands
- NO Norway
- RO Romania
- Sudan SD
- SE Sweden
- SN Senegal SU Soviet Union
- TD Chad
- TG Togo
- United States of America US

8

Find authenticated court documents without watermarks at docketalarm.com.

4

DOCKET

-1-

INSULINOTROPIC HORMONE

Cross-Reference to Related Applications

This application is a continuation-in-part of United States Patent Application Serial No. 859,928, filed on May 5, 1987.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention is directed to the discovery that certain peptide fragments of the prehormone, proglucagon, possess hormonal activities and can be used to stimulate the synthesis and secretion of the hormone, insulin. These peptide fragments are useful in therapy for the disease <u>Diabetes mellitus</u>.

Description of the Background Art

The endocrine secretions of the pancreatic islets are under complex control not only by blood-borne metabolites (glucose, amino acids, catecholamines, etc.), but also by

DOCKET

local paracrine influences. The major pancreatic islet hormones (glucagon, insulin, and somatostatin) interact among their specific cell types (A, B, and D cells, respectively) to modulate secretory responses mediated by the metabolites. Although insulin secretion is predominantly controlled by blood levels of glucose, glucagon and somatostatin stimulate and inhibit glucose-mediated insulin secretory responses, respectively. In addition to the proposed interislet paracrine regulation of insulin secretion, there is evidence to support the existence of insulinotropic factors in the intestine. This concept originates from the observations that glucose taken orally is a much more potent stimulant of insulin secretion than is a comparable amount of glucose given intravenously.

The human hormone, glucagon, is a 29-amino acid peptide hormone produced in the A-cells of the pancreas. The hormone belongs to a multi-gene family of structurally related peptides that include secretin, gastric inhibitory peptide, vasoactive intestinal peptide, and glicentin. These peptides variously regulate carbohydrate metabolism, gastrointestinal mobility, and secretory processing. The principal recognized actions of pancreatic glucagon, however, are to promote glycogenolysis and gluconeogenesis, resulting in an elevation of blood sugar levels. In this regard, the actions of glucagon are counterregulatory to those of insulin and may contribute to the hyperglycemia that accompanies <u>Diabetes mellitus</u> (Lund, P.K., <u>et al.</u>, <u>Proc. Natl. Acad. Sci.</u>, <u>USA</u> <u>79</u>:345-349 (1982)).

Glucagon has been found to be capable of binding to specific receptors which lie on the surface of insulinproducing cells. Glucagon, when bound to these receptors, stimulates the rapid synthesis of cAMP, by these cells. cAMP, in turn, has been found to stimulate insulin expression (Korman, L.Y., <u>et al.</u>, <u>Diabetes 34</u>:717-722 (1985)). Insulin acts to inhibit glucagon synthesis (<u>Review of Medical Physiology</u>, Ganong, W.F., 1979, Lang Publications, Los Altos, California (p. 273)). Thus, the expression of glucagon is carefully regulated by insulin, and ultimately by the serum glucose level.

The glucagon gene is initially translated from a 630base pair precursor to form the polypeptide, preproglycagon (Lund <u>et al.</u> (1982)). This polypeptide is subsequently processed to form proglucagon. Patzelt, C., <u>et</u> al. (Nature 282:260-266 (1979)) demonstrated that proglucagon was subsequently cleaved into glucagon and a second polypeptide. Subsequent work by Lund, P.K., et al. (Proc. Natl. Acad. Sci. USA 79:345-349 (1982)); Lopez, L.C., et al. (Proc. Natl. Acad. Sci. USA 80:5485-5489 (1983)) and Bell, G.I., et al. (Nature 302:716-718 (1983)) demonstrated that the proglucagon molecule was cleaved immediately after lysine-arginine dipeptide residues. Studies of proglucagon produced by channel catfish (Ictalurus punctata) indicated that glucagon from this animal was also proteolytically cleaved after adjacent lysine-arginine and arginine-arginine dipeptide residues (Andrews, P.C., et al., J. Biol. Chem. 260:3910-3914 (1985)). Lopez, L.C., et al. (Proc. Natl. Acad. Sci. USA 80:5485-5489 (1983)), and Bell, G.I., et al., discovered the mammalian proglucagon was cleaved at lysine-arginine or arginine-arginine dipeptides and demonstrated that the proglucagon molecule contained three discrete and highly homologous peptide molecules which were designated glucagon, glucagon-like protein 1 (GLP-1), and glucagonlike protein 2 (GLP-2). Lopez et al. concluded that glucagon-like protein 1 was 37 amino acid residues long

DOCKET

ARM

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

